Valuation: Onconic Therapeutics Inc.

Market Cap 675B 486M 424M 400M 363M 680M 46.61B 683M 4.79B 1.85B 23.7B 1.82B 1.78B 76.24B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 622B 448M 391M 369M 335M 627M 42.97B 630M 4.42B 1.7B 21.85B 1.68B 1.64B 70.3B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.62%
Yield 2024 *
-
Yield 2025 -
1 day-1.72%
1 week-0.60%
Current month-17.58%
1 month+6.14%
3 months-5.59%
6 months-40.80%
Current year-23.99%
1 week 14,420
Extreme 14420
15,600
1 month 13,820
Extreme 13820
18,620
Current year 8,790
Extreme 8790
28,900
1 year 8,790
Extreme 8790
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 2019-12-31
Director of Finance/CFO 50 2019-12-31
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 2019-12-31
Director/Board Member 59 2019-12-31
Director/Board Member 44 2024-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
4/22/25 Exercice 50,000 0.4595%
4/18/25 Exercice

Chief Technology Officer

12,500 0.1149%
4/17/25 Exercice

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
-1.72%-0.60%+31.80% - 486M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
-3.21%-7.27%-17.10%+356.10% 26.21B
+0.50%+7.13%+33.27%+16.01% 26.34B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
-1.26%-7.81%+156.15%+320.43% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.25B
Average -0.70%+1.64%+35.55%+207.33% 27.53B
Weighted average by Cap. -0.47%+1.44%+35.37%+147.74%

Financials

2024 2025
Net sales 14.84B 10.68M 9.31M 8.79M 7.99M 14.96M 1.02B 15.02M 105M 40.65M 521M 40.12M 39.23M 1.68B 53.39B 38.43M 33.51M 31.64M 28.74M 53.84M 3.69B 54.06M 379M 146M 1.87B 144M 141M 6.03B
Net income -8.09B -5.83M -5.08M -4.8M -4.36M -8.16M -559M -8.19M -57.45M -22.17M -284M -21.88M -21.4M -914M 15.78B 11.36M 9.91M 9.35M 8.49M 15.92M 1.09B 15.98M 112M 43.24M 554M 42.68M 41.73M 1.78B
Net Debt -42.69B -30.73M -26.8M -25.3M -22.98M -43.05M -2.95B -43.23M -303M -117M -1.5B -115M -113M -4.82B -52.61B -37.87M -33.02M -31.18M -28.31M -53.05M -3.63B -53.27M -373M -144M -1.85B -142M -139M -5.94B
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
26-09-18 ₩14,860.00 -1.72% 175,530
26-09-17 ₩15,120.00 +3.56% 231,321
26-09-16 ₩14,600.00 -0.68% 103,952
26-09-15 ₩14,700.00 +0.48% 341,984
26-09-14 ₩14,630.00 -2.14% 291,895
  1. Stock Market
  2. Stocks
  3. A476060 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!